Accelerated Titration Designs

Statistical Methods for Dose-Finding Experiments

Volumn , Issue , 2006, Pages 91-113

  Dancey, Janet ^a   Freidlin, Boris ^b   Rubinstein, Larry ^b  

^a DCTD   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Accelerated titration dose escalation designs; Dose escalation de escalation and dose limiting toxicity (DLT); First in man phase I trial design; Four dose escalation designs; Intrapatient dose escalation and dose toxicity model; Model based analysis; Performance evaluation; Risk benefit relationship in phase I trials

Indexed keywords

RISK ASSESSMENT; TOXICITY;

DOSE ESCALATION; DOSE LIMITING TOXICITY; IN-PHASE; MODEL-BASED ANALYSIS; PERFORMANCE EVALUATIONS; PHASE I; TOXICITY MODELING;

TITRATION;

EID: 40449127796     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470861258.ch4     Document Type: Chapter

References (47)

1. S.G. Arbuck (1996) Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann. Oncology, 7(6), 567-73.
2. E.A. Eisenhauer, P.J. O'Dwyer, M. Christian and J.S. Humphrey (2000). Phase I clinical trial design in cancer drug development. J. Clin. Oncology, 18(3), 684-92.
3. S.F. Dent and E.A. Eisenhauer (1996) Phase I trial design: are new methodologies being put into practice? Ann. Oncology, 7(6), 561-6.
4. L.B. Sheiner (1990) Implications of an alternative approach to dose-response trials. J. Acquired Immune Deficiency Syndrome, 3(Suppl. 2), 20-6.
5. L.B. Sheiner, S.L. Beal and N.C. Sambol (1989) Study designs for dose-ranging. Clin. Pharmacology Theory, 46(1), 63-77.
6. L.B. Sheiner, Y. Hashimoto and S.L. Beal (1991) A simulation study comparing designs for dose ranging. Statistics in Medicine, 10(3), 303-21 March.
7. R. Simon, B. Freidlin, L. Rubinstein, S.G. Arbuck, J. Collins and M.C. Christian (1997) Accelerated titration designs for phase I clinical trials in oncology. J. Natl Cancer Inst., 89(15), 1138-47.
8. T.C. Chou and P. Talalay (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochemistry, 115(1), 207-16.
9. T.C. Chou and P. Talalay (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regulation, 22, 27-55.
10. P.M. LoRusso, S. Prakash, A. Wozniak, L. Flaherty, M. Zalupski, A. Shields, H. Sands, R. Parchment and B. Jasti (2002) Phase I clinical trial of 5-fluoropyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU). Investigational New Drugs, 20(1), 63-71.
11. M.P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A.A. Adjei, J. Sloan, P. Atherton, V. Vasile, S. Salazaar, A. Adjei, G. Croghan and C. Erlichman (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer J. Clin. Oncology, 23(6), 1078-87.
12. J.L. Grem, G. Morrison, X.D. Guo, E. Agnew, C.H. Takimoto, R. Thomas, E. Szabo, L. Grochow, F. Grollman, J.M. Hamilton, L. Neckers and R.H. Wilson (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncology, 23(9), 1885-93.
13. C. Sessa, G. Capri, L. Gianni, F. Peccatori, G. Grasselli, J. Bauer,M. Zucchetti, L. Viganò, A. Gatti, C. Minoia, P. Liati, S. Van den Bosch, A. Bernareggi, G. Camboni and S. Marsoni (2000) Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oncology, 11(8), 977-83.
14. K. Mross, M.E. Scheulen, T. Licht, C. Unger, H. Richly, A.C. Stern, K. Kutz, M.G. Camboni, P. Barbieri, E. Verdi, B. Vincenzi and A. Bernareggi (2004) Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Anticancer Drugs, 15(1), 15-22.
15. R. Plummer,M. Ghielmini, P. Calvert, M. Voi, J. Renard, G. Gallant, E. Gupta, H. Calvert and C. Sessa (2002) Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin. Cancer Res., 8(9), 2788-97.
16. S. Mani, H. McDaid, A. Hamilton, H. Hochster, M.B. Cohen, D. Khabelle, T. Griffin, D.E. Lebwohl, L. Liebes, F. Muggia and S.B. Horwitz (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res., 10(4), 1289-98.
17. J. Abraham, M. Agrawal, S. Bakke, A. Rutt, M. Edgerly, F.M. Balis, B. Widemann, L. Davis, B. Damle, D. Sonnichsen, D. Lebwohl, S. Bates, H. Kotz and T. Fojo (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncology, 21(9), 1866-73.
18. S.M. Gadgeel, A. Wozniak, R.R. Boinpally, R. Wiegand, L.K. Heilbrun, V. Jain, R. Parchment, D. Colevas, M.B. Cohen and P.M. LoRusso (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res., 11(17), 6233-9.
19. S.D. Undevia, N.J. Vogelzang, A.M. Mauer, L. Janisch, S. Mani and M.J. Ratain (2004) Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs, 22(4), 449-58.
20. P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.M. Kissmeyer, K. Krasilnikoff, J. Bergh, M.O. Karlsson, A. Lönnebo and J. Ahlgren (2002) A phase I study of CHS 828 in patients with solid tumor malignancy. Clin. Cancer Res., 8(9), 2843-50.
21. M.A. Rudek, W.D. Figg, V. Dyer, W. Dahut, M.L. Turner, S.M. Steinberg, D.J. Liewehr, D.R. Kohler, J.M. Pluda and E. Reed (2001) Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncology, 19(2), 584-92.
22. S. Syed, C. Takimoto, M. Hidalgo, J. Rizzo, J.G. Kuhn, L.A. Hammond, G. Schwartz, A. Tolcher, A. Patnaik, S.G. Eckhardt and E.K. Rowinsky (2004) A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res., 10(19), 6512-21.
23. G.J. Rustin, S.M. Galbraith, H. Anderson, M. Stratford, L.K. Folkes, L. Sena, L. Gumbrell and P.M. Price (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncology, 21(15), 2815-22.
24. A. Chatterjee, R. Digumarti, R.N. Mamidi, K. Katneni, V.V. Upreti, A. Surath, M.L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam and N.R. Srinivas (2004) Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study. J. Clin. Pharmacology, 44(7), 723-36.
25. M.A. Villalona-Calero, S.G. Eckhardt, G. Weiss, M. Hidalgo, J.H. Beijnen, C. van Kesteren, H. Rosing, E. Campbell, M. Kraynak, L. Lopez-Lazaro, C. Guzman, D.D. Von Hoff, J. Jimeno and E.K. Rowinsky (2002) A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin. Cancer Res., 8(1), 75-85.
26. Y.J. Ko, G.J. Bubley, R. Weber, C. Redfern, D.P. Gold, L. Finke, A. Kovar, T. Dahl and S.D. Gillies (2004) Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J. Immunotherapy, 27(3), 232-9.
27. S. Goel, K. Desai, A. Bulgaru, A. Fields, G. Goldberg, S. Agrawal, R. Martin, M. Grindel and S. Mani (2003) A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin. Cancer Res., 9(11), 4069-76.
28. H.X. Chen, J.L. Marshall, E. Ness, R.R. Martin, B. Dvorchik, N. Rizvi, J. Marquis, M. McKinlay, W. Dahut and M.J. Hawkins (2000) A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin. Cancer Res., 6(4), 1259-66.
29. P. Borchmann, R. Schnell, I. Fuss, O. Manzke, T. Davis, L.D. Lewis, D. Behnke, C.Wickenhauser, P. Schiller, V. Diehl and A. Engert (2002) Phase I trial of the novel bispecific molecule H22 × Ki-4 in patients with refractory Hodgkin lymphoma. Blood, 100(9), 3101-7.
30. S.M. Gadgeel, R.R. Boinpally, L.K. Heilbrun, A.Wozniak, V. Jain, B. Redman, M. Zalupski, R. Wiegand, R. Parchment and P.M. LoRusso (2003) A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration '2B' design. Investigational New Drugs, 21(1), 63-74.
31. N.E. Schoemaker, C. van Kesteren, H. Rosing, S. Jansen, M. Swart, J. Lieverst, D. Fraier, M. Breda, C. Pellizzoni, R. Spinelli, M. Grazia Porro, J.H. Beijnen, J.H. Schellens and W.W. ten Bokkel Huinink (2002) A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer, 87(6), 608-14.
32. Y. Matsumura, M. Gotoh, K. Muro, Y. Yamada, K. Shirao, Y. Shimada, M. Okuwa, S. Matsumoto, Y. Miyata, H. Ohkura, K. Chin, S. Baba, T. Yamao, A. Kannami, Y. Takamatsu, K. Ito and K. Takahashi (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncology, 15(3), 517-25.
33. S. Clive, D.J. Webb, A. MacLellan, A. Young, B. Byrne, L. Robson, J.F. Smyth and D.I. Jodrell (2001) Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin. Cancer Res., 7(10), 3071-8.
34. Y. Matsumura, T. Hamaguchi, T. Ura, K. Muro, Y. Yamada, Y. Shimada, K. Shirao, T. Okusaka, H. Ueno, M. Ikeda and N. Watanabe (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer, 91(10), 1775-81.
35. M.J. de Jonge, J. Verweij, A. van der Gaast, O. Valota, O. Mora, A.S. Planting, M.A. Mantel, S.V. Bosch, M.J. Lechuga, F. Fiorentini, D. Hess and C. Sessa (2002) Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur. J. Cancer, 38(18), 2407-15.
36. A.C. Lockhart, M. Howard, K.R. Hande, B.J. Roth, J.D. Berlin, F. Vreeland, A. Campbell, E. Fontana, F. Fiorentini, C. Fowst, V.A. Paty, O. Lankford and M.L. Rothenberg (2004) A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res., 10(2), 468-75.
37. A.J. Ten Tije, J. Verweij, A. Sparreboom, A. Van Der Gaast, C. Fowst, F. Fiorentini, J. Tursi, A. Antonellini, M. Mantel, C.M. Hartman, G. Stoter, A.S. Planting and M.J. De Jonge (2003) Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin. Cancer Res., 9(8), 2957-64.
38. J. Dupont, B. Bienvenu, C. Aghajanian, S. Pezzulli, P. Sabbatini, P. Vongphrachanh, C. Chang, C. Perkell, K. Ng, S. Passe, L. Breimer, J. Zhi, M. DeMario, D. Spriggs and S.L. Soignet (2004) Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors. J. Clin. Oncology, 22(16), 3366-74.
39. R. Salazar, D. Bissett, C. Twelves, L. Breimer,M. DeMario, S. Campbell, J. Zhi, S. Ritland and J. Cassidy (2004) A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7-or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors. Clin. Cancer Res., 10(13), 4374-82.
40. S. Wadler, D. Makower, C. Clairmont, P. Lambert, K. Fehn and M. Sznol (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncology, 22(9), 1553-63.
41. J. Murren, M. Modiano, C. Clairmont, P. Lambert, N. Savaraj, T. Doyle and M. Sznol (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer Res., 9(11), 4092-100.
42. P.H. Jones, R.D. Burnett, I. Fainaru, P. Nadolny, P. Walker, Z. Yu, D. Tang-Liu, T.S. Ganesan, D.C. Talbot, A.L. Harris and G.J. Rustin (2003) A phase 1 study of tazarotene in adults with advanced cancer. Br. J. Cancer, 89(5), 808-15.
43. S.E. Al-Batran, A. Atmaca, F. Bert, D. Jäger, C. Frisch, A. Neumann, J. Orth, A. Knuth and E. Jäger (2004) Dose escalation study for defining the maximum tolerated dose of continuous oral trofosfamide in pretreated patients with metastatic lung cancer. Onkologie, 27(6), 534-8.
44. E.C. Dees, S.D. Baker, S. O'Reilly, M.A. Rudek, S.B. Davidson, C. Aylesworth, K. Elza-Brown, M.A. Carducci and R.C. Donehower (2004) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res., 11(2 Pt 1), 664-71.
45. B.C. Goh, M.J. Ratain, D. Bertucci, R. Smith, S. Mani, N.J. Vogelzang, R.L. Schilsky, M. Hutchison, M. Smith, S. Averbuch and E. Douglass (2001) Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J. Clin. Oncology, 19(5), 1476-84.
46. E. Horstmann, M.S. McCabe, L. Grochow, S. Yamamoto, L. Rubinstein, T. Budd, D. Shoemaker, E.J. Emanuel and C. Grady (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J. Medicine, 352(9), 895-904.
47. R. Kurzrock and R.S. Benjamin (2005) Risks and benefits of phase 1 oncology trials, revisited. N. Engl. J. Medicine, 352(9), 930-2.